Reappraisal of Fibrosis-4 Index and Non-alcoholic Fatty Liver Disease Fibrosis Score for Advanced Fibrosis in Average-risk Population

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Nov 21

PMID 36405611

Authors

Huiyul Park

Eileen L Yoon

Mimi Kim

Jonghyun Lee

Seon Cho

Dae Won Jun

Eun-Hee Nah

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The current cut-offs for fibrosis-4 (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS) are suboptimal for screening because of low accuracy and high false-negative rates in average-risk populations. This study aimed to reappraisal the performance of FIB-4 and NFS in such average-risk populations.

Methods: This is a cross-sectional study, which retrospectively reviewed the magnetic resonance elastography (MRE) data of 8,522 subjects. Individuals with history of significant alcohol consumption and those with positive viral serologic markers were excluded. Finally, 6,215 average-risk individuals were analyzed.

Results: The area under the receiver operating characteristic curves (AUROCs) of FIB-4 for the diagnosis of advanced hepatic fibrosis was higher than that in the NFS especially in the metabolically healthy. The AUROCs of FIB-4 for in the average-risk population was also higher than that in the NFS (0.840 in FIB-4 vs. 0.798, = 0.036). However, the sensitivity of FIB-4 and NFS was low (69.6 and 61.4%, respectively) in applying the current cut-off of FIB-4 [1.3 (2.0)] and NFS [-1.455 (0.12)]. At cut-off of FIB-4 at 1.0, sensitivity (90.2%), and negative predictive value (99.7%) were improved.

Conclusion: The diagnostic performance of FIB-4 was better than that of NFS for screening hepatic fibrosis in average-risk populations. It is recommended to use FIB-4 rather than NFS, when screening for hepatic fibrosis in general population.

Citing Articles

Association between liver fibrosis and osteoporosis in adults aged 50 and older: insights from the Bushehr Elderly Health Program.

Soltani A, Aghakhani A, Dehghanbanadaki H, Majidi Z, Rezaei-Tavirani M, Shafiee G J Diabetes Metab Disord. 2025; 24(1):65.

PMID: 39927178 PMC: 11803014. DOI: 10.1007/s40200-025-01574-z.

Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease.

Wang D, Zhou B, Xiang L, Chen X, Feng J World J Gastroenterol. 2024; 30(25):3132-3139.

PMID: 39006380 PMC: 11238669. DOI: 10.3748/wjg.v30.i25.3132.

Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis.

Park H, Yoon E, Kim M, Kim H, Kim M, Kim Y Sci Rep. 2024; 14(1):7189.

PMID: 38531925 PMC: 10965918. DOI: 10.1038/s41598-024-56085-3.

Suboptimal reliability of FIB-4 and NAFLD-fibrosis scores for staging of liver fibrosis in general population.

Hazzan R, Abu Ahmad N, Habib A, Saleh I, Ziv N JGH Open. 2024; 8(2):e13034.

PMID: 38380260 PMC: 10877654. DOI: 10.1002/jgh3.13034.

Undiagnosed Cirrhosis and Hepatic Encephalopathy in a National Cohort of Veterans With Dementia.

Bajaj J, Silvey S, Rogal S, OLeary J, Patton H, Morgan T JAMA Netw Open. 2024; 7(1):e2353965.

PMID: 38294815 PMC: 10831576. DOI: 10.1001/jamanetworkopen.2023.53965.

References

Park H, Yoon E, Kim M, Cho S, Kim J, Won Jun D . Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea. J Clin Med. 2022; 11(6). PMC: 8953170. DOI: 10.3390/jcm11061474. View

Yin M, Talwalkar J, Glaser K, Manduca A, Grimm R, Rossman P . Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5(10):1207-1213.e2. PMC: 2276978. DOI: 10.1016/j.cgh.2007.06.012. View

Furlan A, Tublin M, Yu L, Chopra K, Lippello A, Behari J . Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol. 2019; 214(1):W20-W26. DOI: 10.2214/AJR.19.21267. View

Lee Y, Yoo Y, Jung Y, Kim J, Seo Y, Yim H . Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2020; 11(4):e00157. PMC: 7263657. DOI: 10.14309/ctg.0000000000000157. View

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View

Kanwal F, Shubrook J, Adams L, Pfotenhauer K, Wong V, Wright E . Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021; 161(5):1657-1669. PMC: 8819923. DOI: 10.1053/j.gastro.2021.07.049. View

Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K . Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2018; 17(4):630-637.e8. PMC: 6294709. DOI: 10.1016/j.cgh.2018.05.059. View

Estes C, Chan H, Chien R, Chuang W, Fung J, Goh G . Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther. 2020; 51(8):801-811. PMC: 7154715. DOI: 10.1111/apt.15673. View

Hu P, Sheng M, Liu Y, Zhang C . FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation. Hum Cell. 2022; 35(6):1752-1765. DOI: 10.1007/s13577-022-00760-y. View

10.

Nah E, Cho S, Kim S, Chu J, Kwon E, Cho H . Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. BMJ Open. 2021; 11(3):e046529. PMC: 7993338. DOI: 10.1136/bmjopen-2020-046529. View

11.

Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell G . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846-54. DOI: 10.1002/hep.21496. View

12.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

13.

Paik J, Kabbara K, Eberly K, Younossi Y, Henry L, Younossi Z . Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2021; 75(5):1204-1217. DOI: 10.1002/hep.32228. View

14.

Xue F, Cheng J, Liu Y, Cheng C, Zhang M, Sui W . Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice. Signal Transduct Target Ther. 2022; 7(1):259. PMC: 9339545. DOI: 10.1038/s41392-022-01054-3. View

15.

Shah S, Dhami-Shah H, Kamble S, Shukla A . FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2020; 73(1):216-217. DOI: 10.1016/j.jhep.2019.12.025. View

16.

Oh H, Won Jun D, Saeed W, Nguyen M . Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016; 22(3):327-335. PMC: 5066376. DOI: 10.3350/cmh.2016.0049. View

17.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

18.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

19.

Zhang M, Sui W, Xing Y, Cheng J, Cheng C, Xue F . Angiotensin IV attenuates diabetic cardiomyopathy suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis. Theranostics. 2021; 11(18):8624-8639. PMC: 8419053. DOI: 10.7150/thno.48561. View

20.

Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M . Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020; 20(4):908-917.e11. DOI: 10.1016/j.cgh.2020.12.016. View